The UKIPO’s recent report on patent, trademark and design applications, publications and grants 1995–2017 has identified some interesting filing trends. Meanwhile, the UK government has confirmed that EU IP rights will continue to be protected in the UK post-Brexit at no-cost to brand owners.
The European Commission is seeking to make it easier to place generic drugs on the market on expiry of SPC protection. Eric Enderlin outlines the implications.
It has become common practice in modern advertising for innovation-driven companies to shout about the patent rights protecting their products, including marking products with patent numbers. Doing so also acts as a deterrent to infringers and can increase the likelihood of successfully claiming damages where infringement does occur. However, the practice does not come without risks, as Eric Siecker explains.
The administrative procedure for obtaining a patent in Japan is similar to that of most other patent systems, and includes the examination of novelty, inventive step and industrial application of the invention.
IP isn’t always the first priority for a business preparing for an initial public offering (IPO); however, the sooner you start thinking about your IP assets, the better prepared you’ll be.
The UK’s Minister for Intellectual Property, Sam Gyimah MP, confirmed on 26 April that the UK has ratified the Unified Patent Court (UPC) agreement.
In its Decision T 1311/13 of 17 January 2018 (re: EP 1 224 299), the EPO’s Board of Appeal has provided clarification as to late-filed requests in appeal proceedings.
The judgment of the Court of Cassation of 6 December 2017, in the case between TEVA and MERCK (patent owner), is the outcome of a long and complex affair concerning the nullity of the French part of the European Patent (EP) n°0724444 describing a dosage regime.
Professor Daryl Lim, keynote speaker at Novagraaf’s January event ‘An Evening at the Embassy’ in Washington, DC, on the importance of fostering understanding and dialogue between IP stakeholders.